Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Abstract LB-066: A high-throughput screen of an annotated small molecule library identifies substrates of P-glycoprotein

Tobie D. Lee, Olivia W. Lee, Kyle R. Brimacombe, Min Shen, Lu Chen, Rajarshi Guha, Bethelihem Tebase, Robert W. Robey, Suresh V. Ambudkar, Michael M. Gottesman, Matthew D. Hall

Cancer Res (2018) 78 (13_Supplement): LB-066.

https://doi.org/10.1158/1538-7445.AM2018-LB-066

Published: 01 July 2018

View articletitled, Abstract LB-066: A high-throughput screen of an annotated small molecule library identifies substrates of P-glycoprotein

Journal Articles

Abstract 4040: Short-term romidepsin treatment combined with clotrimazole or bifonazole leads to decreased mitochondrial hexokinase 2 and apoptosis in cancer cells

Robert W. Robey, Andrew J. McDonald, Hanna Kozlowski, Michael M. Gottesman, Susan E. Bates

Cancer Res (2017) 77 (13_Supplement): 4040.

https://doi.org/10.1158/1538-7445.AM2017-4040

Published: 01 July 2017

View articletitled, Abstract 4040: Short-term romidepsin treatment combined with clotrimazole or bifonazole leads to decreased mitochondrial hexokinase 2 and apoptosis in cancer cells

Journal Articles

Abstract 1771: Metabolic reprogramming in KRAS mutant cancer cells may cause sensitivity to the histone deacetylase (HDAC) inhibitor romidepsin

Agnes Basseville, Carole Sourbier, Robert W. Robey, Dan L. Sackett, W. Marston Linehan, Susan E. Bates

Cancer Res (2015) 75 (15_Supplement): 1771.

https://doi.org/10.1158/1538-7445.AM2015-1771

Published: 01 August 2015

View articletitled, Abstract 1771: Metabolic reprogramming in KRAS mutant cancer cells may cause sensitivity to the histone deacetylase (HDAC) inhibitor romidepsin

Journal Articles

Abstract 5536: Short-term romidepsin treatment combined with MAPK pathway inhibition results in decreased mitochondrial hexokinase 2, increased mitochondrial Bim and apoptosis in BRAF mutant cancers

Susan E. Bates, Victoria Luchenko, Agnes Basseville, Julian Bahr, Arup R. Chakraborty, Andrew McDonald, Alexandra Zimmer, Richard L. Piekarz, Robert W. Robey

Cancer Res (2014) 74 (19_Supplement): 5536.

https://doi.org/10.1158/1538-7445.AM2014-5536

Published: 01 October 2014

View articletitled, Abstract 5536: Short-term romidepsin treatment combined with MAPK pathway inhibition results in decreased mitochondrial hexokinase 2, increased mitochondrial Bim and apoptosis in BRAF mutant cancers

Journal Articles

HG-829 Is a Potent Noncompetitive Inhibitor of the ATP-Binding Cassette Multidrug Resistance Transporter ABCB1

Gisela Caceres, Robert W. Robey, Lubomir Sokol, Kathy L. McGraw, Justine Clark, Nicholas J. Lawrence, Said M. Sebti, Michael Wiese, Alan F. List

Cancer Res (2012) 72 (16): 4204–4213.

https://doi.org/10.1158/0008-5472.CAN-12-0743

Published: 14 August 2012

View articletitled, HG-829 Is a Potent Noncompetitive Inhibitor of the ATP-Binding Cassette Multidrug Resistance Transporter ABCB1

Includes: Supplementary data

Journal Articles

Histone Deacetylase Inhibitors Influence Chemotherapy Transport by Modulating Expression and Trafficking of a Common Polymorphic Variant of the ABCG2 Efflux Transporter

Agnes Basseville, Akina Tamaki, Caterina Ierano, Shana Trostel, Yvona Ward, Robert W. Robey, Ramanujan S. Hegde, Susan E. Bates

Cancer Res (2012) 72 (14): 3642–3651.

https://doi.org/10.1158/0008-5472.CAN-11-2008

Published: 15 July 2012

View articletitled, Histone Deacetylase Inhibitors Influence Chemotherapy Transport by Modulating Expression and Trafficking of a Common Polymorphic Variant of the ABCG2 Efflux Transporter

Includes: Supplementary data

Journal Articles

Abstract 4709: Combined mitogen-activated protein kinase pathway inhibition with short-term romidepsin treatment induces proapoptotic Bim and cell death in BRAF mutant cancers

Robert W. Robey, Victoria L. Luchenko, Julian Bahr, Arup R. Chakraborty, Alexandra S. Zimmer, Richard L. Piekarz, Susan E. Bates

Cancer Res (2012) 72 (8_Supplement): 4709.

https://doi.org/10.1158/1538-7445.AM2012-4709

Published: 15 April 2012

View articletitled, Abstract 4709: Combined mitogen-activated protein kinase pathway inhibition with short-term romidepsin treatment induces proapoptotic Bim and cell death in BRAF mutant cancers

Journal Articles

Abstract 2624: Elevated expression of phosphorylated mitogen activated protein kinase kinase (MEK) as a mechanism of resistance to the histone deacetylase inhibitor romidepsin in HUT 78 cutaneous T-cell lymphoma cells

Arup R. Chakraborty, Robert W. Robey, Nathan Collie, Jean-Pierre Gillet, Richard L. Piekarz, Michael M. Gottesman, Susan E. Bates

Cancer Res (2011) 71 (8_Supplement): 2624.

https://doi.org/10.1158/1538-7445.AM2011-2624

Published: 15 April 2011

View articletitled, Abstract 2624: Elevated expression of phosphorylated mitogen activated protein kinase kinase (MEK) as a mechanism of resistance to the histone deacetylase inhibitor romidepsin in HUT 78 cutaneous T-cell lymphoma cells

Journal Articles

Abstract 2620: Identification of cell context specific and pleiotropic effects of the histone deacetylase inhibitors romidepsin (depsipeptide) and vorinostat (SAHA)

Victoria L. Luchenko, Thomas Litman, Christopher Devor, Aaron Heffner, Robert W. Robey, Julia Wilkerson, Arup R. Chakraborty, Lois Bangiolo, David Levens, Susan E. Bates

Cancer Res (2011) 71 (8_Supplement): 2620.

https://doi.org/10.1158/1538-7445.AM2011-2620

Published: 15 April 2011

View articletitled, Abstract 2620: Identification of cell context specific and pleiotropic effects of the histone deacetylase inhibitors romidepsin (depsipeptide) and vorinostat (SAHA)

Journal Articles

Abstract 2610: Histone deacetylase inhibitors mediate pharmacological rescue of the ABCG2 Q141K variant: Potential for therapeutics in cancer and gout

Agnes Basseville, Akina Tamaki, Caterina Ierano, Yvona Ward, Robert W. Robey, Ramanujan Hegde, Susan E. Bates

Cancer Res (2011) 71 (8_Supplement): 2610.

https://doi.org/10.1158/1538-7445.AM2011-2610

Published: 15 April 2011

View articletitled, Abstract 2610: Histone deacetylase inhibitors mediate pharmacological rescue of the ABCG2 Q141K variant: Potential for therapeutics in cancer and gout

Journal Articles

Abstract 1739: Reversal of ABCB1- and ABCG2-mediated drug resistance by sildenafil

Amit K. Tiwari, Zhi Shi, Suneet Shukla, Robert W. Robey, Satyakam Singh, In-Wha Kim, Susan E. Bates, Xing-xiang Peng, Ioana Abraham, Suresh V. Ambudkar, Tanaji T. Talele, Li-wu Fu, Zhe-Sheng Chen

Cancer Res (2011) 71 (8_Supplement): 1739.

https://doi.org/10.1158/1538-7445.AM2011-1739

Published: 15 April 2011

View articletitled, Abstract 1739: Reversal of ABCB1- and ABCG2-mediated drug resistance by sildenafil

Journal Articles

Abstract 2633: Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration

Caterina Ierano, Kin Wah To, Robert W. Robey, Susan E. Bates, Stefania Scala

Cancer Res (2011) 71 (8_Supplement): 2633.

https://doi.org/10.1158/1538-7445.AM2011-2633

Published: 15 April 2011

View articletitled, Abstract 2633: Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration

Journal Articles

Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance

Zhi Shi, Amit K. Tiwari, Suneet Shukla, Robert W. Robey, Satyakam Singh, In-Wha Kim, Susan E. Bates, Xingxiang Peng, Ioana Abraham, Suresh V. Ambudkar, Tanaji T. Talele, Li-Wu Fu, Zhe-Sheng Chen

Cancer Res (2011) 71 (8): 3029–3041.

https://doi.org/10.1158/0008-5472.CAN-10-3820

Published: 13 April 2011

View articletitled, Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance

Includes: Supplementary data

Journal Articles

Abstract 3541: Pharmacological chaperones increase membrane expression of ABCG2 harboring the Q141K single nucleotide polymorphism

Akina Tamaki, Ierano Caterina, Suneet Shukla, Robert W. Robey, Suresh V. Ambudkar, Susan E. Bates

Cancer Res (2010) 70 (8_Supplement): 3541.

https://doi.org/10.1158/1538-7445.AM10-3541

Published: 15 April 2010

View articletitled, Abstract 3541: Pharmacological chaperones increase membrane expression of ABCG2 harboring the Q141K single nucleotide polymorphism

Journal Articles

Abstract 3528: Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in TM1 of ABCG2

Caterina Ierano, Orsolya Polgar, Akina Tamaki, Bradford Stanley, Yvona Ward, Di Xia, Nadya Tarasova, Robert W. Robey, Susan E, Bates

Cancer Res (2010) 70 (8_Supplement): 3528.

https://doi.org/10.1158/1538-7445.AM10-3528

Published: 15 April 2010

View articletitled, Abstract 3528: Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in TM1 of ABCG2

Journal Articles

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

Chun-ling Dai, Amit K. Tiwari, Chung-Pu Wu, Xiao-dong Su, Si-Rong Wang, Dong-geng Liu, Charles R. Ashby, Jr., Yan Huang, Robert W. Robey, Yong-ju Liang, Li-ming Chen, Cheng-Jun Shi, Suresh V. Ambudkar, Zhe-Sheng Chen, Li-wu Fu

Cancer Res (2008) 68 (19): 7905–7914.

https://doi.org/10.1158/0008-5472.CAN-08-0499

Published: 30 September 2008

View articletitled, Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

Includes: Supplementary data

Journal Articles

Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2–Mediated Drug Resistance

Zhi Shi, Xing-Xiang Peng, In-Wha Kim, Suneet Shukla, Qiu-Sheng Si, Robert W. Robey, Susan E. Bates, Tong Shen, Charles R. Ashby, Jr., Li-Wu Fu, Suresh V. Ambudkar, Zhe-Sheng Chen

Cancer Res (2007) 67 (22): 11012–11020.

https://doi.org/10.1158/0008-5472.CAN-07-2686

Published: 15 November 2007

View articletitled, Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2–Mediated Drug Resistance

Journal Articles

Bisindolylmaleimide and indolocarbazole protein kinase (PK) inhibitors reverse ABCG2-mediated drug transport and resistance

Robert W. Robey, Suneet Shukla, Kenneth Steadman, Suresh V. Ambudkar, Susan E. Bates

Cancer Res (2006) 66 (8_Supplement): 146.

Published: 15 April 2006

View articletitled, Bisindolylmaleimide and indolocarbazole protein kinase (PK) inhibitors reverse ABCG2-mediated drug transport and resistance

Journal Articles

ABCG2 Harboring the Gly482 Mutation Confers High-Level Resistance to Various Hydrophilic Antifolates

Assaf Shafran, Ilan Ifergan, Eran Bram, Gerrit Jansen, Ietje Kathmann, Godefridus J. Peters, Robert W. Robey, Susan E. Bates, Yehuda G. Assaraf

Cancer Res (2005) 65 (18): 8414–8422.

https://doi.org/10.1158/0008-5472.CAN-04-4547

Published: 15 September 2005

View articletitled, ABCG2 Harboring the Gly482 Mutation Confers High-Level Resistance to Various Hydrophilic Antifolates

Journal Articles

Phase II trial of depsipeptide in patients with T-cell lymphoma: Review of responses and surrogate marker analysis

Richard L. Piekarz, Robin Frye, Zhirong Zhan, Robert W. Robey, Kenneth Steadman, Alex Sparreboom, Tito Fojo, John Wright, William D. Figg, Susan E. Bates

Cancer Res (2005) 65 (9_Supplement): 937.

Published: 01 May 2005

View articletitled, Phase II trial of depsipeptide in patients with T-cell lymphoma: Review of responses and surrogate marker analysis

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract LB-066: A high-throughput screen of an annotated small molecule library identifies substrates of P-glycoprotein

Abstract 4040: Short-term romidepsin treatment combined with clotrimazole or bifonazole leads to decreased mitochondrial hexokinase 2 and apoptosis in cancer cells

Abstract 1771: Metabolic reprogramming in KRAS mutant cancer cells may cause sensitivity to the histone deacetylase (HDAC) inhibitor romidepsin

Abstract 5536: Short-term romidepsin treatment combined with MAPK pathway inhibition results in decreased mitochondrial hexokinase 2, increased mitochondrial Bim and apoptosis in BRAF mutant cancers

HG-829 Is a Potent Noncompetitive Inhibitor of the ATP-Binding Cassette Multidrug Resistance Transporter ABCB1

Histone Deacetylase Inhibitors Influence Chemotherapy Transport by Modulating Expression and Trafficking of a Common Polymorphic Variant of the ABCG2 Efflux Transporter

Abstract 4709: Combined mitogen-activated protein kinase pathway inhibition with short-term romidepsin treatment induces proapoptotic Bim and cell death in BRAF mutant cancers

Abstract 2624: Elevated expression of phosphorylated mitogen activated protein kinase kinase (MEK) as a mechanism of resistance to the histone deacetylase inhibitor romidepsin in HUT 78 cutaneous T-cell lymphoma cells

Abstract 2620: Identification of cell context specific and pleiotropic effects of the histone deacetylase inhibitors romidepsin (depsipeptide) and vorinostat (SAHA)

Abstract 2610: Histone deacetylase inhibitors mediate pharmacological rescue of the ABCG2 Q141K variant: Potential for therapeutics in cancer and gout

Abstract 1739: Reversal of ABCB1- and ABCG2-mediated drug resistance by sildenafil

Abstract 2633: Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration

Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance

Abstract 3541: Pharmacological chaperones increase membrane expression of ABCG2 harboring the Q141K single nucleotide polymorphism

Abstract 3528: Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in TM1 of ABCG2

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2–Mediated Drug Resistance

Bisindolylmaleimide and indolocarbazole protein kinase (PK) inhibitors reverse ABCG2-mediated drug transport and resistance

ABCG2 Harboring the Gly482 Mutation Confers High-Level Resistance to Various Hydrophilic Antifolates

Phase II trial of depsipeptide in patients with T-cell lymphoma: Review of responses and surrogate marker analysis

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only